Streetbeat News

Price Targets

CLDX

Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Celldex Therapeutics (NASDAQ:CLDX) and maintained a price target of $67. This reaffirmation highlights the firm's positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 5:51 pm

FDX

B of A Securities analyst Ken Hoexter maintains a Buy rating on FedEx (NYSE:FDX) and raises the price target from $313 to $346.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 5:50 pm

JAZZ

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and maintained a $180 price target.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 5:49 pm

LUNR

Cantor Fitzgerald analyst Andres Sheppard has maintained an Overweight rating on Intuitive Machines (NASDAQ:LUNR) but has lowered the price target from $13 to $10.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 5:48 pm

HQY

Keybanc analyst Scott Schoenhaus maintains an Overweight rating on HealthEquity (HQY) and raises the price target from $85 to $95.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 5:46 pm

NVDA

UBS analyst Timothy Arcuri maintains a Buy rating on NVIDIA (NASDAQ:NVDA) and raises the price target from $800 to $1100.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 5:45 pm

COLD

Keybanc analyst Craig Mailman has maintained an Overweight rating on Americold Realty Trust (COLD) but lowered the price target from $37 to $32.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 5:45 pm

AIR

Benchmark analyst Josh Sullivan reiterates a Buy rating on AAR Corp (NYSE:AIR) and maintains a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 5:44 pm

LULU

Keybanc analyst Ashley Owens maintains an Overweight rating on Lululemon Athletica (LULU) but lowers the price target from $570 to $515.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 5:42 pm

BIOL

Benchmark analyst Bruce Jackson has maintained a Speculative Buy rating on Biolase (NASDAQ:BIOL) but has significantly lowered the price target from $2.5 to $0.4.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 5:42 pm